郑州微飒生物科技有限责任公司 咨询热线：0371-88821766
行业动态

行业动态

追踪行业前沿，洞察产业趋势

药效评价Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

期刊：Bioorganic & medicinal chemistry letters发表年份：2009作者：Alam Jahangir; Muzaffar Alam; David S Carter; Michael P Dillon; Daisy Joe Du Bois; Anthony P D W Ford; Joel R Gever; Clara Lin; Paul J Wagner; Yansheng Zhai; Jeff Zira
阅读更多 →

药效评价Design and synthesis of piperazinylpyridine derivatives as novel 5-HT1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS).

期刊：Chemical & pharmaceutical bulletin发表年份：2009作者：Akira Asagarasu; Teruaki Matsui; Hiroyuki Hayashi; Satoru Tamaoki; Yukinao Yamauchi; Michitaka Sato
阅读更多 →

药效评价Use of aequorin for G protein-coupled receptor hit identification and compound profiling.

期刊：Methods in molecular biology (Clifton, N.J.)发表年份：2009作者：Stephen J Brough; Parita Shah
阅读更多 →

药效评价Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 dopamine receptors.

期刊：ChemMedChem发表年份：2009作者：Marc Vendrell; Aroa Soriano; Vicent Casadó; José Luis Díaz; Rodolfo Lavilla; Enric I Canela; Carme Lluís; Rafael Franco; Fernando Albericio; Miriam Royo
阅读更多 →